Veröffentlichungen
Highlits vom Kongress ASCO 2022 zur Therapie mit CDK4/6-Inhibitoren
Statement Dr. med. Thomas Göhler zur PALOMA-2-Studie: Postmenopausale Frauen mit HR+ / HER2- metastaiertem Brustkrebs ohne Vorbehandlung
Febrile neutropenia (FN) risk assessment and granulocyte colony-stimulating factor (G-CSF) guideline adherence in patients with solid tumours or lymphoma – results from a German prospective multicentre observational study (PROTECT)
April 2012
- Autoren: C. Kurbacher, H. Eschenburg, C.-C. Steffens, M. Schmidt, B. Otremba, K. Hübel, H. Eustermann, A. Friebel, T. Goehler
- DGHO 2012
Interimanalysis of Overall Survival per subgroups in the prospective, non-interventional INSIGHT Study in patients with hepatocellular carcinoma treated with Sorafenib
März 2012
- Autoren: Ganten T.M., Schott E., Galle P.R., Göhler T., Malfertheiner P., Stauber R., Buder R., Achilles K., Gerken G.
- ESMO 2012
Reduced HFSR incidence observed in a randomized phase II study in advanced breast cancer patients treated with Sorafenib and Paclitaxel by initial ramp-up dose escalation (PASO)
Februar 2012
- Autoren: Overkamp, Steffens, Abenhardt, Lerchenmüller, Nusch, Göhler, Groschek, Hegewisch-Becker,Marschner, Rösel, Salat and Decker
- DKK 2012
Trastuzumab treatment in patients with advanced breast cancer (ABC) confined to locoregional and skeletal sites – Results from a large non-interventional study
Januar 2012
- Autoren: Christian Jackisch, Winfried Schoenegg, Johannes Selbach, Manfred Welslau, Hanns-Detlev Harich, Jan Schroeder, Marcus Schmidt, Thomas Goehler, Axel Hinke, Heidi Eustermann, Ralf Ringel
- ASCO 2012
First interim results from a non-interventional study in hepatocellular carcinoma patients treated with sorafenib – the INSIGHT study
April 2011
- Autoren: PD Dr. T.M. Ganten, Department of Internal Medicine, University of Heidelberg, Germany
- Co-Authoren: E. Schott, T. Göhler, R. Wiest, P. Malfertheiner, R. Stauber, R. Buder, K. Achilles, G. Gerken
- DGHO 2011